---
title: "Nitrosamines Update EMA/409815/2020 Rev.22"
description: "On 17 May 2025, the European Medicines Agency (EMA) released Revision 22 of its Nitrosamines Q&A document (EMA/409815/2020), bringing key updates for pharmaceutical manufacturers and regulatory professionals."
url: https://qbdgroup.com/zh-cn/regulatory-updates/nitrosamines-update-rev-22
type: "Regulatory update"
language: zh-cn
published: 2025-06-02
author: "Pablo Palomar, Senior Toxicology Officer"
category: "Regulatory Affairs"
publisher: "QbD Group"
citation: "QbD Group, \"Nitrosamines Update EMA/409815/2020 Rev.22\", https://qbdgroup.com/zh-cn/regulatory-updates/nitrosamines-update-rev-22"
---
# Nitrosamines Update EMA/409815/2020 Rev.22
> On 17 May 2025, the European Medicines Agency (EMA) released Revision 22 of its Nitrosamines Q&A document (EMA/409815/2020), bringing key updates for pharmaceutical manufacturers and regulatory professionals.

## What is new?

In the latest EMA Q&A Rev.22 update, the same risk-based approach is now applied across all routes of administration, with the previous allowance for route-specific justifications removed.

A negative result from a well-conducted in vivo transgenic rodent (TGR) mutagenicity study (OECD 488) is now sufficient to classify N-nitrosamines as non-mutagenic impurities (NMIs), allowing control under ICH Q3A(R2)/Q3B(R2) limits.

Additionally, changes to shelf life and storage conditions to comply with interim acceptable intakes (AIs) are to be implemented without delay, following the guideline on variation classification (see Q&A 13).

These updates reflect EMA’s ongoing commitment to science-based, risk-proportionate regulation—and open new opportunities for smarter impurity control strategies.

## What does this mean to you?

While this is a relatively minor update, it is particularly useful for Marketing Authorization Holders (MAHs) who were unsure about which in vivo studies to design in order to justify classifying a specific nitrosamine as a non-mutagenic impurity (NMI). It also reinforces the principle that the route of administration should not be considered when setting nitrosamine limits—offering a broader safety margin for patients

[![CTA RA update pharma](https://no-cache.hubspot.com/cta/default/7030766/interactive-185447666596.png)](https://qbdgroup.com/hs/cta/wi/redirect?encryptedPayload=AVxigLIJfhkZX07cQTU8hQhTpPf1NG8ks0wmaINhIddkOYshuE2RTo7jCXI6F3VYkzBI8%2FyR2SODc%2FMDFgcvc4oeQzfUyKg1JU9PK8BSuC0%2BV6SlyA94FBQ%2FknNPtFAcq93B1GyGoYExosBNbvhofPzuXmd5%2BubIV2mgKfpcg5fX0DoTssdF32WQNKVtN8qrL8Ry26sqGV6fCul3gzJfLVxJ1X6BKA%3D%3D&webInteractiveContentId=185447666596&portalId=7030766)
---
Source: https://qbdgroup.com/zh-cn/regulatory-updates/nitrosamines-update-rev-22 — © QbD Group. Quote freely with attribution and a link back.